Becton Dickinson & Co Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $22.5B+11.4% YoYTTM through 30 Jun 2026
Net Income $942M-44.8% YoYTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 21.6% |
| Operating Margin | 10.7% |
| Net Margin | 4.2% |
Returns
3.9%ROE
1.9%ROA
2.3%ROIC
Balance Sheet Health
Debt / Equity0.69x
Current Ratio0.87x
Net Debt$16.1B
Cash & Equivalents$708M
Quality Metrics
Altman Z-Score2.19
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $21.8B
Diluted EPS$3.31TTMFY2025: $5.82
Dividend
$2.10Per share, FY20261.15%Yield-4.0%5-yr growth
Capital Allocation
R&D Spend$1.3B
Capex Intensity3.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Medical | $11.5B | +13.7% | View detailsReorganized into Medical Essentials, Connected Care, and BioPharma Systems effective October 1, 2025. |
| Interventional | $5.2B | +4.8% | View detailsMaintained as a core segment under the Excellence Unleashed strategy. |
| Life Sciences | $5.2B | -0.5% | View detailsBiosciences and Diagnostic Solutions businesses combined with Waters Corporation in February 2026, eliminating the segment. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.